Complementary Medications and outcomes in CCTG trials.

Palliative and supportive care presentation at ESMO 2019

Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by the Canadian Cancer Trials Group (CCTG) also used complementary medicines (CMs).

More >>
 
CCTG IND234 prostate precision medicine trial - Dr. Kim Chi

Innovative study advances personalized medicine for prostate cancer patients

CCTG IND224 is a new clinical trial, opening across Canada, is considered a major advancement in precision medicine for prostate cancer and the first of its kind in the world.

More >>
 
CCTG LY16 | RELEVANCE published in New England Journal of Medicine

CCTG LY16 | RELEVANCE published in New England Journal of Medicine

The results of the CCTG LY16 trial of Rituxmab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE), recently published in New England Journal of Medicine, has the potential to offer a new treatment option to lymphoma patients, that does not require chemotherapy.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 

Planned trials

ALC5

Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)

More >>

CRC9

Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca

ENC1

Carboplatin & Paclitaxel with or without Pembrolizumab for Measurable Stage 3 or 4A, Stage 4B or Recurrent Endometrial Cancer

More >>

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

LY18

A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma

More >>

MAC25

Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Breast Cancer

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>

Recently activated

BRC7

INSIGNA: Firstline Immunotherapy alone or in Combination with Chemo in Induction/Maintenance or Post Progression in Adv NSCLC with Immunobiomarker SIGNature-driven Analysis

More >>

HNC2

Radiotherapy with Concurrent MEDI4736 vs Radiotherapy with Concurrent Cetuximab in Pts with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

More >>

I238

Durvalumab Ttreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity

More >>

MAC26

Testing the Addition of the Study Drug Olaparib to the Usual Radiotherapy in Inflammatory Breast Cancer Patients

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 
Award recipients

Canadian Cancer Research Alliance announces award winners

Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.

More >>
 

Publications

Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).

J Clin Oncol 37, 2019
Olson D;Bao R;Allred JB;Strand C;Zha Y;Carll TC;Labadie B;Bastos BR;Butler MO;Munster PN;Schwartz GK;Luke JJ;

More >>

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-a2b for resected high-risk melanoma.

J Clin Oncol 37, 2019
Tarhini AA;Lee SJ;Hodi FS;Rao UNM;Cohen GI;Hamid O;Hutchins LF;Sosman JA;Kluger HM;Sondak VK;Koon HB;Lawrence DP;Kendra KL;Minor DR;Lee CB;Albertini MR;Flaherty LE;Petrella TM;Kirkwood JM;

More >>

PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).

J Clin Oncol 37, 2019
Harshman LC;Puligandla M;Haas NB;Allaf M;Drake CG;McDermott DF;Signoretti S;Cella D;Gupta RT;Shuch BM;Choueiri TK;Lara P;Kapoor A;Heng DYC;Jewett MAS;Master VA;Michaelson MD;Leibovich BC;Maskens D;Carducci MA;

More >>

Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.

J Clin Oncol 37, 2019
Sparano JA;Gray RJ;Makower DF;Lively TG;Saphner TJ;Keane MM;Gomez HL;Reddy PS;Goggins TF;Mayer IA;Toppmeyer D;Brufsky A;Goetz MP;Hayes DF;Dees EC;Pritchard KI;Geyer CE;Olson JA;Albain KS;Sledge GW;

More >>

Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.

J Clin Oncol 37, 2019
Sweeney C;Martin AJ;Zielinski RR;Thomson A;Tan TH;Sandhu SK;Reaume MN;Pook DW;Parnis F;North SA;McDermott R;McCaffrey J;Marx GM;Lawrence NJ;Horvath L;Frydenberg M;Chowdhury S;Chi KN;Stockler MR;Davis ID;

More >>

Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC)(Alliance A021202).

J Clin Oncol 37, 2019
Bergsland EK;Mahoney MR;Asmis TR;Hall N;Kumthekar P;Maitland ML;Niedzwiecki D;Nixon AB;O'Reilly EM;Schwartz LH;Strosberg JR;Meyerhardt JA;

More >>

Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693).

J Clin Oncol 37, 2019
Parulekar WR;Berrang T;Kong I;Rakovitch E;Theberge V;Gelmon KA;Chia SKL;Bellon JR;Jagsi R;Ho AY;White JR;Zellars RC;Bane A;Boileau J;Lemieux J;Montenegro A;Chen BE;Whelan TJ;

More >>